Highly pure neurotoxic component of a botulinum toxin, process for preparing same, and uses thereof
US-9937245-B2 · Apr 10, 2018 · US
Highly pure neurotoxic component of a botulinum toxin and uses thereof
US10653754B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10653754-B2 |
| Application number | US-201815881135-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 26, 2018 |
| Priority date | Jul 30, 2013 |
| Publication date | May 19, 2020 |
| Grant date | May 19, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a process for preparing a highly pure neurotoxic component of a botulinum toxin by cultivating Clostridium botulinum under conditions that allow production of a botulinum toxin, and isolating the neurotoxic component from the botulinum toxin. In addition, the present invention relates to a highly pure neurotoxic component of a botulinum toxin obtainable by the process of the present invention and uses thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A highly pure neurotoxic component of a Clostridium botulinum toxin having a single-chain content of less than 1.70 wt. %, and a total purity of at least 99.90 wt. %. 2. The highly pure neurotoxic component of claim 1 , further having an endotoxin content of 5.0 IU/ml or less and/or a total aerobic viable cell count of less than 1 cfu/ml. 3. A pharmaceutical composition comprising a highly pure neurotoxic component of a Clostridium botulinum toxin according to claim 1 and one or more pharmaceutically acceptable carriers. 4. A medicament comprising the highly pure neurotoxic component of a Clostridium botulinum toxin according to claim 1 . 5. The highly pure neurotoxic component of claim 1 , having a total purity of at least 99.95 wt. %. 6. The highly pure neurotoxic component of claim 1 , having a total purity of at least 99.99 wt. %. 7. The highly pure neurotoxic component of claim 1 , having an endotoxin content of 1.0 IU/ml or less and/or a total aerobic viable cell count of less than 0.5 cfu/ml. 8. The highly pure neurotoxic component of claim 7 , having a total aerobic viable cell count of 0 cfu/ml. 9. The highly pure neurotoxic component of claim 1 , wherein the single-chain content is <1.20 wt. %. 10. The highly pure neurotoxic component of claim 1 , wherein the single-chain content is less than 1.60 wt. %. 11. The highly pure neurotoxic component of claim 1 , wherein the single-chain content is less than 1.00 wt. %. 12. The highly pure neurotoxic component of claim 1 , wherein the single-chain content is less than 0.80 wt. %. 13. The highly pure neurotoxic component of claim 1 , wherein the neurotoxic component has a biological activity in an LD 50 assay of 4.0 to 8.0 pg protein/LD 50 unit. 14. The highly pure neurotoxic component of claim 1 , wherein the neurotoxic component has a biological activity in an LD 50 assay of 5.0 to 6.0 pg protein/LD 50 unit. 15. The pharmaceutical composition of claim 3 , further comprising one or more additional active substance.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10653754B2 cover?
- The present invention relates to a process for preparing a highly pure neurotoxic component of a botulinum toxin by cultivating Clostridium botulinum under conditions that allow production of a botulinum toxin, and isolating the neurotoxic component from the botulinum toxin. In addition, the present invention relates to a highly pure neurotoxic component of a botulinum toxin obtainable by the p…
- Who is the assignee on this patent?
- Merz Pharma Gmbh & Co Kgaa, Merz Pharmaceuticals Gmbh
- What technology area does this patent fall under?
- Primary CPC classification A61K38/4893. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).